

BeiGene, Ltd.  
Form 8-K  
January 25, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF**  
**THE SECURITIES EXCHANGE ACT OF 1934**

---

Date of Report (Date of earliest event reported): **January 25, 2017**

**BEIGENE, LTD.**

(Exact name of registrant as specified in its charter)

**Cayman Islands**  
(State or other jurisdiction  
of incorporation)

**001-37686**  
(Commission File Number)

**98-1209416**  
(I.R.S. Employer Identification No.)

**c/o Maurant Ozannes Corporate Services (Cayman) Limited**

**94 Solaris Avenue, Camana Bay**

**Grand Cayman KY1-1108**

Edgar Filing: BeiGene, Ltd. - Form 8-K

**Cayman Islands**

(Address of principal executive offices) (Zip Code)

**+1 (345) 949 4123**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01 Other Events.**

On January 25, 2017, BeiGene, Ltd. (the Company) issued a press release announcing the initiation of a global Phase III clinical trial of its investigational Bruton's Tyrosine Kinase ( BTK ) inhibitor, BGB-3111, in patients with Waldenström's macroglobulinemia ( WM ). The study is designed to determine whether the quality of response with BGB-3111 in WM is superior to that of ibrutinib, an approved BTK inhibitor. The full text of the Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release issued on January 25, 2017

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BEIGENE, LTD.**

Date: January 25, 2017

By: /s/ Howard Liang  
Name: Howard Liang  
Title: Chief Financial Officer and Chief Strategy Officer

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release issued on January 25, 2017